A Cancer Biotech Just Became a Battery Company — Here's How to Read That

On July 2, LIXTE Biotechnology Holdings (Nasdaq: LIXT) — a clinical-stage company that has spent years developing cancer drug candidates — completed a merger with NOMAD Transportable Power Systems, a maker of truck-mounted, utility-grade battery energy storage systems. The combined company is renaming itself NOMAD Power Solutions, Inc. and will trade under the ticker NMAD starting July 6. LIXTE's cancer pipeline isn't being wound down as an afterthought, either — the company says it's actively pursuing its disposal.

Read that paragraph again, because it's a pattern every micro-cap investor needs to recognize: a public company with a business in one sector suddenly becomes a company in a completely unrelated, currently-hot sector, using a reverse merger — the same shell-and-swap mechanism that gets abused by promoters looking to skip the IPO process entirely. The question isn't whether this happens (it happens constantly). The question is whether this particular instance is a legitimate operating business finding a new public vehicle, or a story built to catch a wave.

The case for "this one's real." NOMAD isn't a paper entity — it's a five-year-old company with a first-to-market product: semi-trailer-mounted battery systems that deliver a full megawatt of instantaneous power without the months of construction and permitting a fixed installation requires. Per the merger announcement, NOMAD has more than 30 active utility, infrastructure, and strategic customer projects running in 2026, and the deal came with a $6.5 million bridge loan to fund its order backlog ahead of close. That's a real balance sheet commitment tied to real, named contracts — not just a press release with a growth story attached.

The case for caution. The timing lines up suspiciously well with the AI power-demand narrative that's driven a huge amount of speculative capital into anything touching grid infrastructure or energy storage in 2026. LIXTE was already added to the Russell Microcap Index in late June, meaning some of the buying interest here may be mechanical index-fund flow rather than genuine conviction in the new business (see our piece on Russell reconstitution mechanics for how that works). And reverse mergers structurally favor the legacy shell's pre-existing shareholders and insiders over new capital — the terms of exactly who gets diluted and by how much are worth reading in the actual merger agreement, not just the press release.

How to actually evaluate this, if you're looking at NMAD post-merger: ignore the sector-of-the-moment framing entirely and ask the boring questions. Does NOMAD have signed contracts with real revenue attached, or just "active projects" and pipeline talk? What's the combined company's cash runway after the bridge loan converts? How much dilution do new BESS-side shareholders face from the old LIXTE cap table, including that Series D preferred stock convertible into tens of millions of shares? None of those questions require believing or disbelieving the AI power narrative — they just require reading the filings instead of the headline.

The honest answer right now is that we don't know yet whether NOMAD Power Solutions is a genuine infrastructure operator that found a smart way onto a public exchange, or a story stock riding a hot sector into a shell with a fresh coat of paint. We'll be watching the first 10-Q under the new name closely — that's when the real numbers show up.

This article is for informational purposes only and does not constitute investment advice.

Todd Colpron is the Managing Partner of Eliakim Capital, a private investment and strategic advisory firm that manages its own capital while working alongside select family offices and private investors to identify and support exceptional opportunities.